Join the Urothelial Carcinoma group to help and get support from people like you.
Urothelial Carcinoma News
Sensorized T-Shirt Enables Early Discharge After Oncological Urology Surgery
THURSDAY, March 27, 2025 – A wearable T-shirt monitor can help oncological urology patients return home sooner after robotic-assisted surgery, according to a study presented at the 40th annual...
Multiparametric MRI Expedites Treatment in Muscle-Invasive Bladder Cancer
FRIDAY, Jan. 24, 2025 – Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct treatment (TTCT) for patients with muscle-invasive bladder...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...
New Therapy Helps Patients With Tough-to-Treat Bladder Cancers
FRIDAY, Dec. 6, 2024 – There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report. An experimental new drug with the unwieldy name of...
Gilead Announces Plans to Voluntarily Withdraw the U.S. Accelerated Approval for Trodelvy in Metastatic Urothelial Cancer
Foster City, Calif., October 18, 2024 – Gilead Sciences, Inc. today announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy® (sacituzumab govitecan-hziy; SG) for the tr...
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
FRIDAY, Sept. 20, 2024 – Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk muscle-invasive urothelial carcinoma after radical...
Post-Op Keytruda Boosts Bladder Cancer Outcomes
WEDNESDAY, Sept. 18, 2024 – When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cancer-free, a new trial finds. Folks with "high-risk"...
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
FRIDAY, Sept. 6, 2024 – Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma (ccRCC) and...
Ruling Out Other Conditions Needed With Suspected Interstitial Cystitis
WEDNESDAY, Sept. 4, 2024 – Efforts to rule out bladder tumors and tuberculosis are still essential in the follow-up of patients with suspected interstitial cystitis (IC), according to a study...
NECTIN4 Amplifications Predict Outcomes in Metastatic Urothelial Cancer
WEDNESDAY, May 8, 2024 – For patients with metastatic urothelial cancer (mUC), NECTIN4 amplifications predict anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) response and outcomes,...
U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) Mar 07, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with ...
U.S. Food and Drug Administration Grants Full Approval for Balversa to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Balversa® is the First and Only Targeted Therapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Susceptible Fibroblast Growth Factor Receptor Alterations Phase 3 THOR ...
FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Padcev (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 3, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
U.S. Food and Drug Administration Approves Opdivo (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) August 20, 2021 – Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for...
U.S. FDA Grants Regular Approval and Expands Indication for Padcev (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have Previously...